3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
14
Nivolumab
11
Magnetic Resonance Spectroscopy
11
pembrolizumab
10
Specimen Handling
10
cabozantinib
8
Ipilimumab
8
trametinib
6
lenvatinib
6
Temozolomide
6
dabrafenib
4
atezolizumab
4
Lutetium-177
4
Immunoglobulin G
4
Everolimus
4
Disulfides
4
CTLA-4 Antigen
4
selpercatinib
3
Octreotide
3
Cisplatin
3
Carboplatin
3
Capecitabine
3
Bevacizumab
3
fludarabine
2
entrectinib
2
copper dotatate CU-64
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Endocrine
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled